ZyVersa Therapeutics Files 2024 10-K
Ticker: ZVSA · Form: 10-K · Filed: Mar 27, 2025 · CIK: 1859007
| Field | Detail |
|---|---|
| Company | Zyversa Therapeutics, Inc. (ZVSA) |
| Form Type | 10-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
ZyVersa's 2024 10-K is in. Check financials for 2022-2024.
AI Summary
ZyVersa Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly Larkspur Health Acquisition Corp., is involved in the pharmaceutical preparations industry. Key financial data and disclosures for the fiscal years 2022, 2023, and 2024 are included in the filing.
Why It Matters
This filing provides investors with a comprehensive overview of ZyVersa Therapeutics' financial health and operational performance for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, ZyVersa Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for the 10-K)
- 2023 — Fiscal Year End (Comparative financial data)
- 2022 — Fiscal Year End (Comparative financial data)
Key Players & Entities
- ZyVersa Therapeutics, Inc. (company) — Filer of the 10-K
- Larkspur Health Acquisition Corp. (company) — Former name of ZyVersa Therapeutics, Inc.
- 2024-12-31 (date) — Fiscal year end
- 2025-03-27 (date) — Filing date
- 0001859007 (company) — Central Index Key
FAQ
What is the primary business of ZyVersa Therapeutics, Inc.?
ZyVersa Therapeutics, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
When did ZyVersa Therapeutics, Inc. change its name from Larkspur Health Acquisition Corp.?
The company changed its name from Larkspur Health Acquisition Corp. on April 26, 2021.
What is the business address of ZyVersa Therapeutics, Inc.?
The business address is 217 W. MAIN STREET, SOMERVILLE, NJ 08876.
What is the SEC file number for ZyVersa Therapeutics, Inc.'s 10-K filing?
The SEC file number is 001-41184.
What are the different classes of preferred stock mentioned in the filing?
The filing mentions Series A Preferred Stock and Series B Preferred Stock.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding ZyVersa Therapeutics, Inc. (ZVSA).